Compare Johnson & Johnson (JNJ) vs Wipro Limited (WIT) Price & Performance

Johnson & Johnson (JNJ) trades at $250.61, down 0.96% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $2.90 versus $2.84 expected, and revenue growth of 6.6% year-over-year. The stock shows robust profitability with a net income margin of 21.48% and ROE of 26.42%, supported by consistent dividend payments including the recent $1.34 per share declared for H1-2026.

JNJ presents a favorable investment case with analyst consensus price target of $279.33 implying ~11% upside, though rising debt-to-asset ratio to 24.06% in 2025 and volatile cash flow trends pose risks. The healthcare giant's diversified portfolio and raised full-year guidance underpin long-term stability, but investors should monitor execution amid competitive and regulatory pressures.

WIT trades at $1.82, down 2.15% with bearish technical signals. The company reported mixed Q1 2027 results with revenue below expectations but maintains solid profitability with 13.92% net margin. Recent partnerships with ServiceNow and AI initiatives show strategic positioning, though earnings misses in three consecutive quarters raise execution concerns.

The stock faces headwinds from recent earnings disappointments and bearish analyst sentiment (19% buy rating), but attractive valuation (P/E 13.86) and strong cash flow generation ($169.4B operating cash flow in 2025) provide fundamental support. Key risks include client spending uncertainty and competitive pressures in IT services.